A potent D2/D3 antagonist in development for major depressive disorder (MDD) with anhedonia

Anhedonia is a hallmark symptom of MDD. Dysregulated dopaminergic neurotransmission, particularly in brain reward systems, is thought to underlie anhedonia.1

ENX-104 was engineered to directly modulate dopaminergic transmission in brain reward systems by increasing dopamine release via potent antagonism of presynaptic D2/D3 autoreceptors and provides an excellent pharmacokinetic profile that supports once-daily dosing.2

ENX-104 is rapidly advancing into clinical studies, where it is expected to improve symptoms of anhedonia while delivering a favorable safety and tolerability profile.2

No currently approved treatments specifically target anhedonia, a disabling symptom defined as the inability to feel pleasure1 ⁠— modulating dopaminergic reward systems is a novel approach to manage this core feature of MDD

+ References and Abbreviations

D2, dopamine receptor 2; D3, dopamine receptor 3; MDD, major depressive disorder.

1. Belujon P & Grace AA. Int J Neuropsychopharmacol. 2017;20:1036–1046. 2. Engrail Therapeutics. Data on file.